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One limitation of reduced-intensity preparative regimens is potential for graft failure. We have developed
a regimen that targets CD4þ lymphodepletion to ensure early and durable engraftment. The primary endpoint
was achievement of 50% CD3þ donor chimerism by day þ28. Forty-two patients (median age, 53 years;
range, 29 to 73 years) received pentostatin 4 mg/m2 i.v. on days 28, 21, and 14 when the CD4þ cell count
was >100 cells/mL and on days 4 and 3 regardless of CD4þ level. Rituximab 375 mg/m2 was administered
to patients with CD20þ malignancies on days 21, 14, 7, þ1, and þ8. Busulfan 200 mg/m2 i.v. was
administered on days 4 and 2 at a dose to target a cumulative AUC dose of 16,000 (10%) mmol$min/L.
Graft-versus-host disease (GVHD) prophylaxis consisted of tacrolimus plus methotrexate in 86% of patients.
Donors were matched-related (47%), matched unrelated (43%), or mismatched unrelated (10%). Chronic
lymphocytic leukemia (45%) and follicular non-Hodgkin lymphoma (14%) were the most common diagnoses.
Disease status at initiation of the preparative regimenwas complete remission in 22%, partial response in 55%,
and stable/progression in 24%. The median percent CD4þ cell count decrease from baseline (day28) was 52%
to day 21, 66% to day 14, 62% to day 7, and 91% to day 0. At day þ28, all 42 patients (100%) had 50%
CD3þ donor chimerism. No patient experienced graft failure. Overall response rate was 82% (complete
remisson, 67%). The day þ100 cumulative incidence of grade II-IV acute GVHD was 59% (grade III-IV acute
GVHD, 19%), and the 2 year cumulative incidence of chronic GVHD was 69% (moderate/severe, 58%). Non-
relapse mortality was 2% at day þ100 and 17% at 2 years. Two-year PFS was 55%, and OS was 68%. This
regimen ensures durable engraftment, is effective against persistent disease, and results in relatively low
mortality from causes other than relapse.
 2013 American Society for Blood and Marrow Transplantation.INTRODUCTION to suboptimal performance status, pretransplantation
Historically, host conditioning before allogeneic hemato-
poietic cell transplantation (allo-HCT) has focused on
administration of myeloablative doses of chemotherapy or
chemoradiotherapy, aimed at maximal disease cytor-
eduction, but at the cost of signiﬁcant morbidity and
mortality [1-7]. Recognition of the major role of adoptive
immunotherapy, mediated by donor T cells, in disease
eradication after allo-HCT resulted in the development of
less-intensive preparative regimens, which emphasize host
immune suppression to facilitate engraftment and reduce
toxicity. Consequently, less morbidity andmortality has been
observed [8-11]. Reduced-intensity conditioning (RIC) regi-
mens have expanded applicability of allo-HCT to patients not
otherwise eligible to receive myeloablative regimens owinge presented at the 53rd annual meeting
logy, San Diego, California, December 11,
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13.04.020comorbidities, or advanced age. Overcoming the barrier of
host immunity to ensure permanent donor engraftment
remains a limitation of allo-HCT, particularly when using RIC
regimens.
Purine analogs are an integral component of contempo-
rary RIC regimens [12-16], owing to their ability to elicit T cell
immunosuppressive effects [16]. Pentostatin (Nipent; Hos-
pira, Lake Forest, IL) is an ideal agent because of its potent
inhibition of adenosine deaminase, the activity of which is
critical for replication of T and B lymphocytes [17], and less
myelosuppression compared with other purine analogs,
namely ﬂudarabine [18]. A murine model of non-
myeloablative HCT demonstrated that host T cell suppres-
sion, different from T cell depletion, may be a key
determinant of engraftment after conditioning with purine
analogebased regimens. This appears to be better attained
with pentostatin compared with ﬂudarabine [19]. Additional
efforts to further reduce toxicity resulting from allo-HCT
conditioning regimens have exploited once-daily dosing of
i.v. busulfan (Busulfex; Otsuka America Pharmaceutical,
Princeton, NJ) with pharmacokinetic-targeted dosing that
optimizes exposure, aiming at more consistent tumor control
and less drug-related toxicity [13,14,20,21].Transplantation.
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Figure 1. Study schema.
M.A. Kharfan-Dabaja et al. / Biol Blood Marrow Transplant 19 (2013) 1087e10931088Targeted strategies aimed at reducing relapse are also
desirable. One such strategy exploits B cell killing with rit-
uximab, a chimeric murine/human IgG1k anti-CD20þ
monoclonal antibody approved for treatting various
subtypes of B cell lymphomas. Rituximab has been safely
combined with RIC regimens, resulting in encouragingly low
incidence and severity of acute GVHD based on non-
randomized data [22-24].
One limitation of RIC regimens is the potential for early or
late graft failure even in T cellereplete allo-HCT [9,25].
Published data suggest that host immune status at the time
of allo-HCT (using number of previous therapies before allo-
HCT as a surrogate for T cell suppression) is an important
predictor of subsequent donor engraftment. The number of
previous therapies is inversely correlated with host T cell
count, which in turn is directly proportionally correlated
with graft failure in most cases [26]. A higher host T cell
count generally entails a greater risk for mixed chimerism
and graft failure. Accordingly, guiding host CD4þ depletion
could facilitate early durable engraftment in patients
undergoing RIC allo-HCT.
Here we present results of a phase II study evaluating
CD4þ lymphodepleting kinetics of pentostatin combined
with pharmacokinetically targeted i.v. busulfan in patients
undergoing allo-HCT for various hematologic malignancies.
Rituximab was added for patients with CD20þ-expressing
malignancies only.
MATERIALS AND METHODS
This phase II study was conducted at the Blood and Marrow Trans-
plantation Department of the H. Lee Mofﬁtt Cancer Center between March
20, 2008, and April 15, 2011, following approval by the University of South
Florida’s Institutional Review Board. This study has been registered with
ClinicalTrials.gov (NCT 00496340).
Study Endpoints
The primary endpoint was achievement of 50% donor chimerism in
CD3þ peripheral blood lymphocytes by day þ28 ( 7) after allo-HCT.
Secondary endpoints included time to hematologic (ie, absolute neutro-
phil count [ANC] and platelet) engraftment; CD33þ donor chimerism at
days þ28 and þ100; CD3þ donor chimerism at day þ100; nonrelapsemortality (NRM) at dayþ100,1 year, and 2 years; rates of infection and acute
and chronic GVHD; response; progression-free survival (PFS); and overall
survival (OS).Eligibility Criteria
Patient-speciﬁc
Eligibilty criteria included age 18 years, Karnofsky performance score
of 70%, adequate organ function (ie, cardiac left ventricular ejection frac-
tion 50%, creatinine clearance [measured or calculated] >50 mL/min, total
serum bilirubin 2 mg/dL, serum aspartate aminotransferase and alanine
aminotransferase <2 times the institutional upper limit of normal, and
corrected lung CO diffusion capacity 50%), absence of active infection, and
willinginess to provide written informed consent. Patients with myocardial
infarction, cerebrovascular accident (including transient ischemic attack), or
gastrointestinal bleeding within 30 days of enrollment were ineligible.
Previous allo-HCT was another exclusion criterion.
Disease-speciﬁc
Hematologic malignancies included nearly all of those for which allo-
HCT is normally indicated, with the exception of idiopathic myeloﬁbrosis
and multiple myeloma. Patients with the latter were excluded because of
a competing trial.
Donor and cell sources
Donor source included 7/8 or 8/8 HLA (-A, -B, -C, and -DRB1) matched
related or matched unrelated donors. Cord blood was not allowed. All
patients received granuloyte colony-stimulating factoremobilized alloge-
neic peripheral blood stem cells.Conditioning Regimen
The conditioning regimen consisted of 2 phases (Figure 1). In the pre-
conditioning phase, patients received pentostatin 4 mg/m2 i.v. on day 28 if
CD4þ cell count measured between days 30 and 28 was >100 cells/mL.
Second and third doses of pentostatin 4 mg/m2 i.v. were given on days 21
(1) and 14 (1) if CD4þ count >100 cells/mL persisted. Patients received
i.v. hydration with 0.5-1 L of D5W/0.5 normal saline or similar before
and after pentostatin. For patients with CD20þ malignancies, rituximab
375 mg/m2 i.v. was administered on days 21 (1), 14 (1), and 7 (1).
The conditioning phase consisted of busulfan at 200 mg/m2 i.v. over
3 hours on day 4. Blood samples for evaluation of busulfan pharmacoki-
netics were obtained at 0.25, 4, 5, 6, and 7 hours. A second i.v. busulfan dose
was administered on day 2 to target a cumulative area under the curve
(AUC) dose of 16,000 (10%) mmol$min/L. Patients also received pentostatin
4 mg/m2 i.v. over 1-2 hours on days 4 and 3. Day 0 was the day of
hematopoietic cell infusion. Rituximab 375 mg/m2 i.v. was again adminis-
tered on days þ1 and þ8 after allo-HCT.
Table 1
Patient, Disease, and Treatment Characteristics
Characteristics Results
Recipient age, yrs, median (range) 53 (29-73)
Recipient sex, n (%)
Male 31 (74)
Female 11 (26)
Donor/recipient sex match, n (%)
Female/female 4 (10)
Female/male 9 (21)
Male/female 7 (17)
Male/male 22 (52)
Donor source, n (%)
Matched related donor 20 (47)
Matched unrelated donor 18 (43)
Misamatched donor* 4 (10)
CD34 cell dose,  106/kg recipient body
weight, median (range)
8.93 (1.66-14.07)
GVHD prophylaxis, n (%)
TAC-MTX 36 (86)
TAC-sirolimus 4 (10)
TAC-mycophenolate mofetil 2 (5)
Rituximab administration (n, %) 33 (79)
Diagnosis, n (%)
CLL (includes 2 cases of B cell prolymphocytic 19 (45)
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Antiseizure prophylaxis consisted of oral lorazepam 0.5-1.0 mg every
6 hours starting on day 6 and continuing until the evening of day 0, with
the dose adjusted based on tolerance. Oral ursodeoxycholic acid 300 mg
twice daily in patients weighing <70 kg and 600 mg in the morning and
300 mg in the evening in patients weighing 70 kg was provided up to
day þ100 for hepatic prophylaxis. GVHD prophylaxis was not restricted to
a particular regimen. Co-enrollment in a concomitant randomized trial
comparing a combination of tacrolimus (TAC; 0.03 mg/kg/day as a 24-hour
continuous i.v. infusion beginning on day 3 and converted to oral dosing
when permissible to maintain whole blood levels of 5-15 ng/mL) plus i.v.
methotrexate (MTX; 15 mg/m2 on day þ1, then 10 mg/m2 on days þ3, þ6,
and þ11) or mycophenolate mofetil (30 mg/kg/day i.v. in 2 divided doses
beginning day 0, at least 2 hours after the end of cell infusion, later con-
verted to oral formulation as tolerated), was allowed [27]. Later, patients co-
enrolled in a trial comparing TAC þ MTX and TAC þ sirolimus (a 9-mg oral
loading dose on day 1, then 4 mg/day orally to target a therapeutic level of
5-14 ng/mL) [28]. Patients not eligible to participate in the aforementioned
studies received TAC þ MTX.
Prophylaxis for bacterial infection, herpesvirus, and fungal infections
were administered in accordance with institutional guidelines. Prophylaxis
against Pneumocystis jirovecii pneumonia consisted of oral trimethoprim/
sulfamethoxazole or inhaled pentamidine (if allergic to sulfa) from day 28
to day 5, and later resumed on day þ30. Surveillance and preemptive
treatment of cytomegalovirus (CMV) and Epstein-Barr virus (EBV) were
instituted according to institutional guidelines.leukemia)
Follicular NHL 6 (14)
Mantle cell NHL 4 (10)
Acute myelogenous leukemia/myelodysplastic
syndrome
3 (7)
Diffuse large B cell NHL 2 (5)
Transformed NHL 2 (5)
Hodgkin lymphoma 2 (5)
Peripheral T cell NHL not otherwise speciﬁed 2 (5)
T cell prolymphocytic leukemia 1 (2)
Waldeström macroglobulinemia 1 (2)
Disease status at time of allo-HCT, n (%)
CR1/CR2 4 (10)
CR3þ 5 (12)
PR1/PR2 15 (36)
PR3þ 8 (19)
Refractory 10 (24)
Recipient Karnofsky performance score, n (%)
90% 32 (76)
<90% 10 (24)
Donor/recipient CMV serologic status, n (%)
Positive/positive 14 (33)Follow-Up and Outcome Assessment
Donor chimerism assessment using peripheral blood (for CD3þ and
CD33þ) or unsorted bone marrow was performed by STR/PCR on days þ28
(7), þ100 (10), þ365 (30), and þ730 (30), when applicable. Primary
engraftment failure was deﬁned as failure to engraft (neutrophil and/or
platelets) by day þ30 after allo-HCT. Secondary (or late) graft failure was
deﬁned as loss of graft function after initial documented engraftment in
absence of recurrent malignancy. Disease status and response were assessed
before allo-HCT and at 1, 3, 12, and 24 months after allo-HCT when appli-
cable. Response criteria were based on patient’s disease according to pub-
lished guidelines [29-33]. Patients were categorized as complete remission
(CR), partial response (PR), and stable/progressive disease (SD/PD).
Response was assessed on day þ30, day þ90, 1 year, and 2 years after allo-
HCT. Toxicities were assessed throughout the study from pentostatin initi-
ation until hospital discharge, and then every 2 weeks, or as deemed
appropriate by physician, through day 100 (10). All toxicities were
assessed using the National Cancer Institute’s Common Terminology Criteria
for Adverse Events v3. Acute GVHDwas gradedweekly from dayþ7 through
day þ100 according to the Consensus Conference on Acute GVHD Grading
[34]. Chronic GVHD was graded using consensus criteria [35].Positive/negative 5 (12)
Negative/positive 10 (24)
Negative/negative 13 (31)
HCT comorbidity index score, n (%)y
0 15 (36)
1 3 (7)
2 8 (19)
3 16 (38)
NHL indicates non-Hodgkin lymphoma.
* Mismatches were as follows: HLA-A antigen, n ¼ 1; HLA-B allele, n ¼ 1;
HLA-B antigen, n ¼ 1; HLA-C antigen, n ¼ 1.
y Scored according to Sorror et al. [43].Statistical Analysis and Sample Size Calculation
Primary objective was assessment of proportion of patients achieving
50% CD3þ donor chimerism at day þ28 post allo-HCT. Historical data
suggest that approximately 65% of patients receiving RIC regimens for allo-
HCT achieve this landmark [12,36]. We hypothesized that lowering CD4þ
counts with pentostatin, before cell infusion, will increase proportion of
patients achieving 50% CD3þ donor chimerisms to 85% at day þ28.
Accordingly, we estimated that accrual of 41 patients would provide 85%
power to detect this difference with an a value of 0.05 using a 2-sided
binomial test. Stopping rules for futility of engraftment were incorporated
in the design.
Secondary endpoints were assessed using descriptive statistics
including frequency, median, range, and proportions. Cumulative incidence
function with competing-risks analysis was used to estimate engraftment,
acute GVHD, chronic GVHD, and NRM. NRM is deﬁned as death without
disease relapse or progression [37]. OS was estimated using the Kaplan-
Meier method [38]. The dataset was locked for analysis on September 27,
2012. Time-to-neutrophil engraftment was deﬁned as ﬁrst of 3 consecutive
days with an ANC  500/mL. Time-to-platelet engraftment was deﬁned as
ﬁrst of 3 days with platelet counts  20,000/mL without transfusion in prior
7 days.RESULTS
Forty-two patients (31 males; 74%), with a median age of
53 years (range, 29 to 73 years), underwent allo-HCT. Five
had undergone a previous autologous HCT. Patient, disease,
and treatment characteristics are summarized in Table 1.
Median follow-upwas 24months (range, 3 to 48 months) forall patients and 34 months (range, 12 to 49 months) for
surviving patients.
Donor Chimerism
The median percentages of donor CD3þ, CD33þ, and
unsorted bone marrow chimerism analyses are reported in
Table 2. At day þ28, all 42 patients (100%) had 50% CD3þ
donor chimerism. No patients had <60% CD3þ donor
chimerism at day þ28 or day þ90. No patients experienced
primary or secondary graft failure.
CD4þ and CD8þ Lymphodepleting Kinetics
CD4þ data were available for all 42 patients at baseline
(day30 to day28), day21 (1), and day14 (1), but in
Table 2
Kinetics of CD3þ, CD33þ, and Unsorted Bone Marrow Donor Chimerism
Donor Chimerism Day þ28, %
(Median, Range)
(n ¼ 42*)
Day þ100
(Median, Range)
(n ¼ 38*)
CD3þ 87 (61-100) 96 (64-100)
CD33þ 100 (95-100) 100 (100-100)
Bone marrow (unsorted) 96 (64-100) 96 (78-100)
* Bone marrow chimerism data were available for only 38 patients at
day þ28 and for only 36 patients at day þ100.
Table 3
Nonhematologic Toxicities
Variable Grade 0,
n (%)
Grade 1,
n (%)
Grade 2,
n (%)
Grade 3,
n (%)
Grade 4,
n (%)
Oral mucositis 8 (19) 0 (0) 11 (26) 22 (52) 1 (2)
Nausea/vomiting 13 (31) 21 (50) 7 (17) 1 (2) 0 (0)
Enteritis 19 (45) 17 (40) 5 (12) 1 (2) 0 (0)
Renal 26 (62) 9 (21) 1 (2) 5 (12) 1 (2)
Cardiac 26 (62) 10 (24) 4 (10) 2 (5) 0 (0)
Hepatic 29 (69) 11 (26) 2 (5) 0 (0) 0 (0)
Pulmonary 29 (69) 8 (19) 2 (5) 2 (5) 1 (2)
Neurologic 37 (88) 2 (5) 2 (5) 1 (2) 0 (0)
Vascular 37 (88) 1 (2) 0 (0) 2 (5) 2 (5)
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at day 0. The median CD4þ cell count was 343 cells/mL (27-
844 cells/mL) at baseline, 165 cells/mL (33-642 cells/mL) at
day21,116 cells/mL (41-413 cells/mL) at day14,129 cells/mL
(43-344 cells/mL) at day7, and 31 cells/mL (9-161 cells/mL) at
day 0. Only 4 patients had a CD4þ cell count 100 cells/mL
(median, 130 cells/mL; range, 100 to 161 cells/mL) by day 0.
The percentage decrease in median CD4þ count from base-
line was 52% to day 21, 66% to day 14, 62% to day 7, and
91% to day 0 (Figure 2). Similarly, the median CD8þ cell count
was 298 cells/mL (range, 13 to 908 cells/mL) at baseline, 153
cells/mL (range, 12-939 cells/mL) at day 21, 120 cells/mL (9-
399 cells/mL) at day 14, 129 cells/mL (range, 16 to 671 cells/
mL) at day7, and 30 cells/mL (4-326 cells/mL) at day 0. Only 5
patients had a CD8þ cell count of 100 cells/mL (median, 120
cell/mL; range, 105 to 326 cells/mL) by day 0. The percent
decrease in median CD8þ count from baseline was 49% to
day 21, 60% to day 14, 57% to day 7, and 90% to day 0.Pharmacokinetics of i.v. Busulfan
All patients had pharmacokinetic data available after
the ﬁrst busulfan dose. The median AUC value was 8204
mmol$min/L (range, 5830 to 12,116 mmol$min/L); 16 patients
(38%) had an AUC >8800 mmol$min/L, and 12 (26%) had an
AUC <7200 mmol$min/L. For 38 patients with AUC data for
ﬁrst and second doses, the cumulative total median AUC was
17,518 mmol$min/L (range, 15,010 to 21,215 mmol$min/L); 17
patients (45%) had an AUC >17,600 mmol$min/L, and none
had an AUC <14,400 mmol$min/L.Compliance with Treatment and Adherence to Protocol
One patient received day 21 doses of pentostatin and
rituximab 48 hours behind schedule owing to a skin rash
noted at the time of scheduled infusion. A second subject
required postponement of her day 21 dose of pentostatin
and rituximab after her donor tested positive for hepatitis B
surface antigen on repeat donor workup; scheduled doses
of pentostatin and rituximab were administered 7 days
later after the donor was conﬁrmed to be negative for
hepatitis B. Finally, a third patient required postponement ofDay Median CD4 (range) % decrease median CD4
in cells/µL
-28          343 (27-844)                              baseline
-21          165 (33-642) -52%
-14          116 (41-113)                                -66%
-7 129 (43-344) -62%
0 31 (9-161) -91%
Figure 2. Kinetics of CD4þ lymphodepletion.busulfan and pentostatin adminstration because of zoster
reactivation.
Clinical Outcomes
Hematopoietic cell engraftment
All patients engrafted. The median time to ANC engraft-
ment was 17 days (range, 15 to 28 days), and the cumulative
incidence of ANC engraftment by dayþ28 was 100%. Platelet
engraftment occurred at a median of 13 days (range, 0 to
177 days). Ten patients (24%) never had a platelet level below
20,000/mL. The cumulative incidence of platelet engraftment
by day þ28 was 97.6% (95% CI, 90.6%-100%).
Disease responses
At dayþ30 after allo-HCT, the overall response rate (ORR)
in 33 patients undergoing transplantation in less than CRwas
42% (CR, 36%) and increased to 62% (CR, 59%) by dayþ90. The
best observed ORR was 82% (CR, 67%). Seventeen of 19
patients with chronic lymphocytic leukemia (CLL) under-
went allo-HCT in less than CR (PR, n¼13 [PR1, n¼ 2; PR2, n¼
6; PR3þ, n¼ 5]; SD/PD, n¼ 4). The ORR for patients with CLL
was 82% (CR, 53%). Two patients with CLL with SD/PD at the
time of allo-HCTachieved CR. None of the 2 patients with CLL
who underwent allo-HCT in CR progressed. Similarly, 5 of 6
patients with follicular non-Hodgkin lymphoma underwent
allo-HCT in less than CR (PR2, n ¼ 4; SD/PD, n ¼ 2); the ORR
in these patients was 100% (CR, 100%).
Toxicities, adverse events, and causes of death
Table 3 summarizes observed toxicities in descending
frequency. Oral mucositis was the most common. Six
patients (14%) developed grade 3 renal toxicity. Two
patients developed renal toxicity during peri-engraftment
despite baseline creatinine clearance values of 88 mL/min
and 98mL/min; the other 4 patients were considered to have
renal insufﬁciency owing to multifactorial causes, including
infection (adenovirus) and medication (tacrolimus toxicity,
related to therapy for CMV). Three of 5 patients with
a creatinine clearance <70 mL/min (median, 60 mL/min;
range, 52 to 68 mL/min) developed renal toxicity (n ¼ 1 each
grade 1, grade 2, and grade 3); 1 of these cases was associated
with a supratherapeutic TAC level. Three patients (7%)
developed severe pulmonary toxicities owing to CMV
pneumonitis, respiratory failure from volume overload, and
idiopathic pneumonia syndrome. Four (10%) developed
vascular complications with deep vein (n ¼ 2) or catheter-
associated (n ¼ 2) thrombosis; 1 patient developed grade 2
thrombotic microangiopathy while receiving TAC þ siroli-
mus for GVHD prophylaxis. One patient (2%) developed
grade 3 cardiac toxicity manifesting as uremic pericarditis.
No cases of sinusoidal obstructive syndrome were observed.
Figure 3. PFS, all patients.
Figure 4. OS, all patients.
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CMV reactivation requiring preemptive therapy was seen
in 17 patients. Reactivation of EBV was observed in 3 patients
(7%), and 1 patient (2%) developed posttransplantation
lymphoproliferative disorder, which responded to ritux-
imab. Five patients developed viral infections (adenovirus,
n¼ 1 [2%]; herpes simplex esophagitis, n¼ 1 [2%]; norovirus,
n ¼ 1 [2%]; H1N1 inﬂuenza, n ¼ 1 [2%]; and BK cystitis, n ¼ 1
[2%]). There were 2 episodes of lung infections (P jirovecii
pneumonia, n¼ 1 [2%]; ground glass opacity pneumonia, n¼
1 [2%]). One patient (2%) developed infectionwith Aspergillus
sp. in the setting of steroid-refractory chronic GVHD.
GVHD
The median time from allo-HCT to the initiation of TAC
taper was 62 days (range, 38 to 377 days). The median time
to onset of acute GVHDwas 33 days (range, 14 to 85 days). By
day þ100, the cumulative incidence of acute grade II-IV
GVHD was 59% (95% CI, 43%-75%), and that of acute GVHD
grade III-IV was 19% (95% CI, 7%-35%). Only 2 patients
developed late-onset acute GVHD (on days þ104 and þ118)
manifesting as elevated liver enzyme levels with no previous
manifestations of acute GVHD before day þ100. At 2 years,
the cumulative incidence of chronic GVHD of any severity
was 69% (95% CI, 53%-83%), and that of moderate/severe
chronic GVHD was 58% (95% CI, 39%-75%).
Disease progression, NRM, and causes of death
The cumulative incidence of progressionwas 14% (95% CI,
5%-26%) at day þ100 and 30% (95% CI, 17%-44%) at 2 years
after allo-HCT. The cumulative incidence of NRMwas 2% (95%
CI, 0-9%) at day þ100 and 17% (95% CI, 7%-30%) at 2 years
after allo-HCT. Fourteen patients (30%) died, 8 from relapse/
progression (19%), 3 from GVHD (7%), and 1 each (2%) from
infection, secondary malignancy (lung cancer), and multi-
organ failure.
Survival
For all patients, 2-year PFS was 55% (95% CI, 39%-69%) and
OS was 68% (95% CI, 53%-81%) (Figures 3 and 4). Disease
status (CR, PR, or refractory) at the time of HCT did not affect
2-year PFS (P ¼ .60) or OS (P ¼ .99). Patients with CLL had
a 2-year PFS of 55% (95% CI, 32%-78%) and a 2-year OS of 66%
(95% CI, 43%-86%).DISCUSSION
Allo-HCT represents the sole available curative treatment
for various otherwise deadly hematologic malignancies. Theliterature supports using RIC regimens for hematopoietic cell
allografting; however, no published regimen is yet consid-
ered the standard of care, and preferences for particular
regimens are based on institutional biases and physician
familiarity. The optimal preparative regimen for allo-HCT
should ensure a high and durable rate of donor hematopoi-
etic engraftment and effective disease control, particularly in
patients undergoing allo-HCT with active disease. Bishop
et al. [39] have shown that achievement of rapid complete
donor chimerism might be important in inducing a more
potent and durable graft-versus-malignancy effect against
chemorefractory lymphomas in patients undergoing allo-
HCT. A regimen combining pentostatin and low-dose (1 Gy)
total body irradiation (TBI) in a canine model of dog leuko-
cyte antigeneidentical HCT showed that pentostatin
contributed to sustained engraftment in 4 of 10 dogs
compared with 0 of 10 dogs when using 1 Gy TBI alone [40].
The relatively high rate of graft failure in the dogs was
attributed in part to a less profound degree of host T cell
depletion in lymph nodes from 1 Gy compared with 2 Gy,
among other reasons [40]. A previous study in humans
combined pentostatin and low-dose (2 Gy) TBI as a condi-
tioning regimen for allo-HCT [16]. Different from our study,
pentostatin was administered at a dose of 4 mg/m2 on
days 21, 20, and 19, and TBI was performed on day 1.
The authors reported a 49% decrease in CD3þ cell count by
day 7, with more depression in CD4þ cells compared with
CD8þ cells and a median CD3þ donor chimerism of 82.5% by
day þ70 [16]. Miller et al. [15] evaluated a conditioning
regimen incorporating 2 consecutive days (days 7 and 6)
of extracorporeal photopheresis, pentostatin 4 mg/m2/day
i.v. by continuous infusion for 2 days (days 5 and 4), and
6 Gy of TBI (on days 3 and 2), and reported full donor
chimerism in 98% of cases, but a 100-day NRM of 11%, higher
than found in the present study .
The results of this phase II trial demonstrate that pen-
tostatin combined with pharmacokinetically targeted i.v.
busulfan can achieve effective lymphodepletion and is well
tolerated, with a relatively lowNRM and acceptable response
rates with encouraging PFS and OS. In contrast to Pavletic
et al. [16], we found no apparent difference in the degree of
CD4þ cell depletion compared with CD8þ cell depletion in
this study. Administration of pentostatin plus rituximab (in
cases of CD20þ-expressing lymphoid malignancies) starting
at day 28 (Figure 1) provides the beneﬁt of disease control
before allo-HCT in patients sensitive to pentostatin (and
rituximab), such as those with CLL, among others. This study
was not intended to assess response rates after completing
administration of the ﬁrst 3 doses of pentostatin (by
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patients had to abort allo-HCT because of clinical evidence of
disease progression after pentostatin was initiated on
day 28, suggesting that this administration schedule might
help control disease progression, especially considering that
78% of the patients were in less than CR at the time of
regimen initiation.
In this study, administration of pentostatin provided an
effective host-lymphodepleting strategy that facilitated early
robust and durable CD3þ donor engraftment. We selected
achievement of 50% CD3þ donor chimerism on day þ28 as
the primary endpoint because early achievement of this
landmark has been shown to ultimately correlate with
a lower risk of graft failure, both early and late [36]. Similarly,
we found a median CD33þ donor chimerism of 100% at both
day þ28 and day þ100. No patient experienced primary or
secondary graft failure, suggesting that this regimen provides
sufﬁcient immune suppression to facilitate early and durable
donor engraftment without compromising efﬁcacy. This
ﬁnding compares favorably with other similar published RIC
regimens, which have reported graft failure rates of 2%-19%
[36,41], suggesting that targeting of immunosuppression
status to CD4þ cell count <100 cells/uL allows the host
immune barrier to be overcome before infusion of donor
hematopoietic cells, which is necessary to facilitate perma-
nent donor engraftment.
We observed a plateau effect on lymphodepletion with
a median percentage decrease of CD4þ levels of approxi-
mately 66% after administration of ﬁrst 2 doses of pentos-
tatin. This plateau effect was observed in CD8þ cell counts as
well, which decreased to approximately 60% after the second
pentostatin dose (administered on day 21). Future reﬁne-
ment of this regimen could consider omitting at least 1 dose
of pentostatin. Furthermore, the relatively delayed time to
ANC engraftment (median, 17 days) in our study might be
explained by administration of rituximab during the pre/
peri-infusion phase of the regimen, as has been reported
previously [42].
Importantly, pentostatin, when administered according
to the regimen outlined in this study, circumvented the need
for antithymocyte globulin in recipients of unrelated allo-
grafts; this is particularly important when considering that
more than one-half (53%; n ¼ 22) of the cases received an
allograft from an matched unrelated donor (43%) or mis-
matched unrelated donor (10%). Also, the median i.v.
busulfan AUC was 8204 mmol$min/L for the ﬁrst dose and
17,518 mmol$min/L for cumulative 2 doses. These values were
within the intended target AUC of 8000 (10%) mmol$min/L
and 16,000 (10%) mmol$min/L, respectively, indicating that
pharmacokinetic targeting is feasible even if i.v. busulfan
results in AUC variation of approximately 3-fold. In patients
in whom AUC values (whether ﬁrst or cumulative dose)
exceeded the upper cutoff of 10%, no serious hepatic adverse
events were observed. This regimen resulted in a day þ100
cumulative incidence of 59% (95% CI, 43%-75%) for grade II-IV
acute GVHD and 19% (95% CI, 7%-35%) for grade III-IV acute
GVHD. This compares favorably with reported data for
a regimen of ﬂudarabine plus i.v. busulfan, which targeted
a cumulative AUC of approximately 24,000 mmol$min/L, with
a day þ100 cumulative incidence of grade II-IV acute GVHD
of up to 79% at our center [27].
EBV reactivation occurred in 3 patients (7%), none of
whom died. One patient (2%) showed clinical evidence of
posttransplantation lymphoproliferative disorder, requiring
treatment with 4 weekly doses of rituximab 375 mg/m2.None of these 3 patients had received rituximab as part of
a conditioning regimen. Interestingly, these patients’ CD4þ
cell counts at day 0 were 17, 31, and 39 cells/mL, suggesting
that profound lymphodepletion increases the risk of devel-
oping serious infections, including EBV reactivation.
Accordingly, monitoring for EBV is recommended when
using this regimen, particularly in patients with non-CD20þ
malignancies in whom rituximab is not used. Moreover, we
observed CMV reactivation requiring preemptive therapy in
17 subjects. Two subjects developed CMV disease manifest-
ing as CMV pneumonitis and CMV gastritis. All other patients
responded to anti-CMV therapy without serious sequelae.
This relatively high incidence of CMV reactivation might be
explained by the profound degree of immunosuppression
associated with this regimen.
We found a relatively high incidence of grade 3-4 renal
toxicity (14%; 6 of 42 patients). This high incidence is likely
multifactorial, occurring in the setting of severe infection
with sepsis, intravascular volume changes, and possible
nephrotoxicity related to the calcineurin inhibitors used for
GVHD prophylaxis.
This RIC regimen resulted in solid engraftment and was
apparently effective for patients with advanced lymphoid
malignancies, even in the presence of persistent disease,
resulting in encouraging response rates and survival. The
small number of patients with myeloid malignancies (n ¼ 3)
enrolled in our study, as a result of a competing clinical trial,
limits our ability to reach conclusions regarding the efﬁcacy
of this regimen in that particular setting.
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